Category Archives: Global News Feed

REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET, not 5 p.m. ET as previously stated. The corrected release follows:

The rest is here:
CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

BOCA RATON, Fla., April 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO First Wave BioPharma, has issued a Letter to Shareholders to provide an update on recent events and an outlook for the Company’s clinical programs in 2022.

Read the original post:
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders

ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults.

The rest is here:
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

BASEL, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer. The approval is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein.

Read more here:
Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

The rest is here:
Publication of Annual Report and Financial Statements for the Year ended 31 December 2021

New data highlights include:

Here is the original post:
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May

PRESS RELEASE

See original here:
Saniona publishes its Annual Report for 2021

IRVINE, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, will hold a webcast on Monday, May 2, 2022 at 5:00am PT/8:00am ET to review the topline results from the Saturn-2 Phase 3 trial for TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of Demodex blepharitis and provide a brief corporate update.

Original post:
Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual Meeting

Read more here:
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

- Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC - - Reductions in mean annualized anti-VEGF injections ranged from 81% in all patients to 94% in those with NAbs <1:125 at 2 X 10^11 vg/eye -

Original post:
Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting